BioPharma Dive July 9, 2024
Rebecca Pifer

On Tuesday, regulators updated the public on their almost three-year-old probe of PBM’s business practices.

The Federal Trade Commission on Tuesday released a long-awaited report criticizing the pharmacy benefit manager industry for manipulating the drug supply chain to profit at the expense of patients and independent pharmacists.

The report, which focuses on PBMs’ pharmacy practices, builds on research finding the companies are contributing to higher drug costs. It could increase pressure on Congress to curb business practices in the sector alleged to be anticompetitive, after momentum around PBM reform fizzled out late last year.

In the report, the FTC highlights how consolidation has created a market where the six largest PBMs control almost 95% of the prescriptions filed in the...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Govt Agencies, Pharma, Pharma / Biotech
What 14 pharmacy chiefs will prioritize for the next 6 months
What Amazon has done in the first half of 2024
These health care professionals may be secret weapon against hypertension, study says
Podcast: New Alzheimer's Drug Approval Expands Treatment Options – and Creates Coverage Questions
Public Health Matters Video: Walmart is Elevating Specialty Pharmacy Services and Enriching HIV Care

Share This Article